Clear lung inflammation pill in the treatment of community-acquired pneumonia clinical trial scheme

Clear lung inflammation pill in the treatment of community-acquired pneumonia (wind warm disease, pathogenic heat indicates pulmonary syndrome) efficacy and safety of multicenter, randomized, double-blind, placebo-controlled trial research trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-13003883

Enrollment

Unknown

Registered

2013-08-29

Start date

2013-02-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Community-acquired pneumonia

Interventions

The control group:Moxifloxacin Hydrochloride and Sodium Chloride Injection+Ambroxol Hydrochloride Injection+The placebo

The experimental group:Moxifloxacin Hydrochloride and Sodium Chloride Injection+Ambroxol Hydrochloride Injection+Clear lung inflammation pill

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1) conforms to the modern medical diagnostic criteria of community-acquired pneumonia; 2) meet the patient-centered warm disease, pathogenic heat indicates pulmonary syndrome diagnostic criteria; 3) aged 18-65, gender not limited; 4) course of 72 hours or less (not intravenous antibiotics); 5) temperature >=37.5 degree C; 6) CURB-65 score < 3 points; 7) the patient informed and sign the informed consent.

Exclusion criteria

Exclusion criteria: 1) the age of 18 years old or less, at the age of 65 or higher; 2) cough caused by other diseases, including chronic bronchitis and COPD, bronchial asthma, pulmonary fibrosis, pulmonary tuberculosis, whooping cough, acute tonsillitis, fungus, tumor, etc.; 3) CURB-65 grade is 3 or more points; 4) pregnancy or ready to pregnancy, lactation women; 5) security laboratory abnormalities: renal function; CR is greater than the upper limit of normal value; Liver function: ALT, AST > 1.5 times the upper limit of normal person; 6) with severe cardiovascular, liver and kidney hematopoietic system and endocrine system of primary disease, mental illness; 7) allergic constitution or this drug allergies; 8) has a history of drug abuse; 9) involved in other drugs participants nearly three months; 10) don't sign the informed consent.

Design outcomes

Primary

Measure	Time frame
Blood routine examination;CRP;PCT;Liver function;Renal function;Routine urine test;Dung conventional;Blood gas analysis;Sputum culture;Mycoplasma antibodies, condensing set test;Chest computed tomography (CT);ECG;	—

Countries

China

Contacts

Public ContactBaolin Wei

Second Affiliated Hospital of Tianjin University of TCM

weibaolin1961@163.com+86 13512276001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026